Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Gilead Sciences
Woman and Man
Between 18 years
and 99 years
Gilead Sciences
Update Il y a 4 ans
GS-US-312-0123 : Essai de phase 3 randomisé, en double-aveugle, visant à évaluer l’efficacité et la tolérance de l’idélalisib associé à la bendamustine et au rituximab, chez des patients ayant une leucémie lymphoïde chronique non précédemment traitée. [essai clos aux inclusions]
L’objectif de cet essai est d’évaluer l’efficacité et la tolérance de l’idélalisib en association avec de la bendamustine et du rituximab, chez des patients ayant une leucémie lymphoïde chronique. Le...
Country
France
organs
Leucémies chroniques
Specialty
Thérapies Ciblées
,
Chimiothérapie
Essai clos aux inclusions
More information
Woman and Man Max 99 years
Gilead Sciences, Inc
Update Il y a 4 ans
An international study to assess the safety and efficacy of a combination of new investigational drugs in hepatitis C virus infected patients with advanced liver disease or require treatment after liver transplantation
The primary objectives of this study are: • To explore the antiviral efficacy of combination therapy with SOF/LDV FDC + RBV for 12 or 24 weeks in subjects with advanced liver disease (either pre-liver...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Gilead Sciences, Inc
Update Il y a 4 ans
DORADO-AC-EX – A Double-Blind, Active-Controlled, Long-Term Safety Extension Study to the Phase 3 DORADO-AC Study (Protocol DAR-312) of Darusentan in Resistant Hypertension A Double-Blind, Active-Controlled, Long-Term Safety Extension Study of Optimized Doses of Darusentan in Subjects with Resistant Hypertension Despite Receiving Combination Therapy with Three or More Antihypertensive Drugs, Including a Diuretic, as Compared to Guanfacine (Protocol DAR-312-E)
The primary objective of this study is to evaluate the long-term safety of darusentan in subjects with RHTN despite treatment with full doses of three or more antihypertensive medications, including a...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Gilead Sciences, Inc
Update Il y a 4 ans
A study in people with long-lasting hepatitis B to assess the effectiveness and safety of the two drugs Viread and Hepsera. Sudio su persone affette da epatite B da lungo tmepo per valutare l`efficacia e la sicurezza dei due farmaci Viread e Hepsera
-To compare the efficacy of tenofovir DF 300 mg QD versus adefovir dipivoxil 10 mg QD for the treatment of presumed pre-core mutant chronic hepatitis B. To compare the safety and tolerability of te...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Gilead Sciences, Inc
Update Il y a 4 ans
A Phase 3 Randomized, Double-Blind, Placebo-controlled study of Idelalisib (GS-1101) in Combination with Rituximab for Previously Treated CLL
To evaluate the effect of the addition of idelalisib (formerly GS-1101) to rituximab on progression-free survival (PFS) in subjects with previously treated chronic lymphocytic leukemia (CLL).
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Gilead Sciences, Inc
Update Il y a 4 ans
A Randomized, Double-blind, Placebo-controlled Study of Ranolazine in Patients with Heart Failure with Preserved Ejection Fraction
The primary objective of the study is to determine if ranolazine, compared to placebo, will be more effective in improving diastolic function in patients with HFpEF.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Gilead Sciences, Inc
Update Il y a 4 ans
Filgotinib in Combination With Conventional Anti-rheumatic Drugs in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biologic DMARD treatment
The primary objective of this study is to evaluate the effects of filgotinib versus placebo for the treatment of signs and symptoms of rheumatoid arthritis (RA) as measured by the proportion of subjec...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Gilead Sciences, Inc
Update Il y a 4 ans
This study will test an experimental drug called GS-9883/emtricitabine/tenofovir alafenamide (GS-9883/F/TAF) for the treatment of HIV-1 infection. The purpose of this study is to evaluate safety, and to determine whether GS-9883/F/TAF as a fixed dose combination maintains the control of HIV-1 infection effectively compared to treatment with dolutegravir (DTG) (trade name Tivicay) and emtricitabine/tenofovir alafenamide (F/TAF)
To evaluate the efficacy of a fixed dose combination (FDC) containing GS-9883/emtricitabine/tenofovir alafenamide (GS-9883/F/TAF) versus dolutegravir (DTG) + a FDC containing emtricitabine/tenofovir a...
Country
None
organs
None
Specialty
None
unknown
More information
Woman Max 99 years
Gilead Sciences Incorporated
Update Il y a 4 ans
Clinical research study involving an experimental combination medication called EVG/COBI/FTC/TDF. This is 1 pill containing 2 experimental medications, EVG and COBI, plus 2 medications already approved for the treatment of HIV-1 infection, FTC and TDF. In this study neither the patient or the investigator will know whether the patient is receiving EVG/COBI/FTC/TDF or the comparator drug ritonavir-boosted atazanavir with FTC/TDF. This is a randomized (by chance, like a flip of a coin) study
To evaluate the efficacy of a regimen containing elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus emtricitabine/tenofovir disoproxil fumara...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Gilead Sciences, Inc
Update Il y a 4 ans
A study with sofosbuvir and ribavirin for people with Hepatitis C and severe kidney disease
The primary objectives of this study are: * To evaluate the safety of sofosbuvir (SOF) 200mg or 400mg + ribavirin (RBV) for 24 weeks as assessed by review of the accumulated safety data in each treat...
Country
None
organs
None
Specialty
None
Closed trial
More information
Previous
1
2
3
4
5
6
7
8
9
10
Next